Compare AbbVie Inc (ABBV) vs PepsiCo, Inc. (PEP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs PepsiCo, Inc. — how do they compare? AbbVie Inc trades at $249.5 (market cap $438.19B), while PepsiCo, Inc. trades at $138.23 (market cap $187.99B). The key difference: AbbVie Inc is far larger — about 2.3× PepsiCo, Inc.'s market cap, and PepsiCo, Inc. pays the higher dividend (4.3%). Which is the better fit depends on your goals.
| ABBV | PEP | |
|---|---|---|
Market Cap | $438.19B | $187.99B |
Sector | Health | Consumer Staples |
52-Week High | $263.58 | $170.44 |
52-Week Low | $197.38 | $134.95 |
Enterprise Value | $502.45B | $230.48B |
Dividend Yield | 2.79% | 4.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABBV trades at $247.91, up 0.76% today, with a bullish technical signal supported by moving averages and oversold RSI levels. The company reported Q2 2026 EPS of $3.65, beating expectations, and maintains strong profitability with a 71.48% gross margin. Recent news highlights positive Phase 2 data for ELAHERE in ovarian cancer, reinforcing growth prospects beyond Humira's patent expiry.
Outlook is positive with analyst consensus target of $278.69, though high P/E of 70.05 and debt levels pose valuation and financial risks. Revenue growth driven by Skyrizi and Rinvoq offsets competitive pressures, but patent cliffs in the 2030s require monitoring. The stock offers dividend appeal with a $1.73 payout scheduled for August 2026.
PepsiCo (PEP) trades at $137.69, down 0.95% on the day, with a bearish technical signal despite recent earnings beats. The company maintains strong profitability with 10.78% net margin and 51.59% ROE, though Q3 2026 earnings are pending. Recent news highlights price adjustments on snack products and sponsorship changes, while analysts maintain a consensus Buy rating with $158.79 price target.
PEP offers steady dividend income and operational stability, but faces near-term pressure from consumer resistance to price hikes and competitive threats. The stock trades below consensus target with mixed technical indicators, presenting potential value for long-term investors willing to navigate current volatility and margin pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →
